filo
Although Hims & Hers Health (NYSE:HIMS) handily beat Street expectations on both lines in its Q1 financial results and also reiterated 2025 guidance, shares are down ~5% in post-market trading Monday.
For the full year, revenue is projected at $2.3B-$2.4B. Consensus is $2.32B. For Q2, the